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 MicroRNAs (miRNAs), short non-coding RNAs that repress translation of cognate 
sequence-matched mRNAs through multiple mechanisms, are established as both important 
regulators and key biomarkers of cardiovascular function. miRNAs have been shown to modulate 
gene expression resulting in altered development and/or functional responses in every type of 
vascular cell. miRNAs also circulate in plasma, either complexed to lipoproteins or contained 
within extracellular vesicles. Circulation of miRNA enables its functionality both as biomarkers for 
altered gene expression to indicate and describe pathological conditions, and as mediators of 
horizontal gene transfer between vascular cells in autocrine or paracrine fashion. miRNAs are 
well-suited to these roles due to their relatively long half-life (~5 days) that can support long-term 
gene regulation in distal cells. Horizontal transfer of intercellular RNA extends the reach of 
miRNAs beyond their cell of origin and adds new dimensions to gene regulation in vivo. Horizontal 
miRNA transfer may be of particular relevance in post-mitotic and senescent vascular cells, in 
which modulation of gene expression by miRNAs can affect cellular activation in acute or chronic 
settings. In particular, platelets are highly enriched in miRNAs, and platelets are emerging as 
major sources and transfer hubs mediating miRNA exchange in blood. Platelet-derived 
microvesicles (PMVs) constitute a major fraction of plasma MVs, and these structures have been 
shown to deliver platelet miRNAs to other vascular and extravascular cells in multiple contexts. 
Moreover, phagocytosis of intact platelets has been demonstrated in several vascular cell types 
including endothelial cells, neutrophils and monocytes, providing yet another opportunity for 
miRNA exchange by engulfment of whole platelets. The mechanisms, cellular and molecular 
targets, and functional outcomes of horizontal transfer of platelet miRNAs are an active area of 
investigation. Most recently, Zeng et al. reported a new cellular target of platelet miRNAs: vascular 
smooth muscle cells (VSMCs) in vitro following co-incubation with platelets, and in vivo following 
wire injury to the femoral artery in mice, with effects on VSMC injury response [1]. Even more 
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surprising is the apparent engulfment of intact platelets by vascular smooth muscle cells, 
representing not only exchange of genetic material, but exchange of complex cellular content 
between these vascular cells.. In this Neighborhood Watch, we discuss the background, 
implications, unanswered questions, and future perspectives of this study. 
 
Platelet RNA transfer 
The recent report by Zeng et al. [1], builds upon an exciting area of research in the 
cardiovascular field: the ability of platelets to modulate other cells in contact with the blood by 
transferring (mi)RNAs, which then modulate the physiology of the recipient cells. This ability to 
transfer RNAs was first reported in 2012, when the delivery of mRNAs in platelet-like particles 
from the Meg01 cell line to human umbilical vein endothelial cells (HUVECs) and the THP-1 
monocytic cell line was described. In addition, after transfusion of wildtype platelets into TLR2-
deficient mice, TLR2 mRNA was detected in the peripheral blood mononuclear cells (PBMCs), 
suggesting in vivo mRNA transfer [2]. The following year, Laffont et al., reported that PMVs 
contain functional Ago2:miR-223 complexes which could be transferred to HUVECs, leading to 
down-regulation of the levels of FBXW7 and EFNA1 mRNAs [3]. In the subsequent years, PMV 
delivery of miRNAs to many cell types in culture was reported, including hepatocellular carcinoma 
cells, macrophages, lung epithelial cells, natural killer cells, and VSMCs [4]. Utilizing metabolically 
labeled megakaryocyte/platelet RNAs, we recently demonstrated transfer of platelet RNA to 
heterologous cells in vivo. We observed the delivery of multiple platelet-derived miRNAs including 
miR-24 and miR-223 to lung carcinoma cells in ectopic solid tumors in vivo, leading to miR-24-
dependent tumor growth suppression. This effect was abrogated in the platelet thrombin receptor 
PAR4-null mouse, which harbor 50% fewer plasma-borne PMVs compared to wildtype, and was 
restored by PMV transfusion, demonstrating the dependence on PMVs for this process [5]. Zeng 
et al., builds upon this background by demonstrating in vivo transfer of miR-223 to VSMCs 
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following endothelial denudation. They further report the engulfment of whole, activated platelets 
by VSMCs in vitro, and in vivo at the site of mechanical injury to the femoral artery in mice, and 
they relate these phenomena to subsequent inhibition of neointimal hyperplasia. 
 
miR-223 and cardiovascular disease 
 miRNA-223 is the most abundant microRNA present in platelets, and thus there has been 
much interest in studying its roles in cardiovascular function and disease. In one of the first studies 
describing the miRNA content of platelets, Landry et al., identified miR-223-containing Ago2 
complexes in human platelets and demonstrated that miR-223 could regulate the expression of 
P2RY12, the mRNA that encodes the platelet specific adenosine diphosphate (ADP) receptor, 
P2Y12 [6]. While deletion of miR-223 had no effect on in vitro assays of platelet function, Wang et 
al., demonstrated that miR-223-deficient mice had prolonged occlusion times in a model of 
photochemical-induced carotid thrombosis[7, 8], confirming a major role for platelet miRNAs, in 
particular miR-223, in platelet reactivity in vivo. Interestingly, WT platelets or PMVs transfused 
into miR-223-/y mice were able to restore occlusion times and lowered arterial expression of IGF-
1R - a miR-223 target - at the site of injury, suggesting delivery of miR-223 to cells of the vessel 
wall [8]. 
 Because of its abundance, miR-223 has also been utilized as a biomarker for platelet 
function, cardiovascular disease, and diabetes (Reviewed in [9]). Due to its ability to regulate the 
level of P2Y12, there have been several studies reporting that low levels of miR-223 are associated 
with enhanced platelet function in patients using the anti-P2Y12 drug clopidigrel[10]. Lower 
circulating miR-223 levels have also been associated with diabetes  [11] and with increased 
myocardial infarction risk [12]. The inverse relationship between miR-223 levels and platelet 
reactivity and its contributions to cardiovascular disease risk is consistent with the finding of Zeng 
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et al., in which miR-223-deficient mice exhibit increased intimal hyperplasia in response to 
vascular injury, correlating with increased thrombotic risk. 
 
Unanswered questions and challenges 
One of the most significant challenges in understanding the effects of horizontal miRNA 
transfer is isolating the causes: are effects due to the exchanged miRNA, or to exposure of the 
target cells to other properties of the delivery vehicle? Add to this the question of whether delivery 
vehicles themselves are a singular species, and the challenge becomes even greater. In the study 
from Zeng et al., miRNAs appear to be delivered by whole, internalized and activated platelets, 
although close inspection of the images suggests that a large portion of the internalized material 
in VSMCs consists of PMVs, platelet exosomes, or platelet fragments. Enrichment of PMVs 
following platelet activation in vitro, and near a damaged vessel where platelets are becoming 
activated in vivo, would be expected, and PMV uptake by heterologous cells and subsequent 
miRNA transfer from PMVs has been demonstrated in many contexts. Moreover, at least some 
of the internalized platelets in VSMCs appear granulated, suggesting that VSMCs may take up 
platelets at a range of activation states. A related question is the source of whole platelets for 
uptake by exposed VSMCs at sites of vascular damage: are the VSMCs internalizing activated 
platelets directly from the induced thrombus at the injury site or from circulation? The persistence 
of platelet-expressed GFP in the intimal zone seven days after injury could indicate deposition of 
new platelet material during or after thrombus clearance. Ongoing platelet or PMV uptake may 
also provide fresh sources of miRNAs, and this in turn could account for long-term effects on 
neointimal hyperplasia. Altogether, the relative contributions of PMVs and platelets to miRNA 
transfer to VSMCs in the context of vascular injury, the nature of the platelets involved, and 
potentially distinct or compound effects over time, await further study. 
There are alternative explanations for the observations reported by Zeng. et al. Activated 
platelets are well known to contribute to neointimal hyperplasia, and in particular P2Y12 has been 
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strongly implicated: hyperplasia in mice is substantially suppressed both by P2Y12 deletion and 
by treatment with ticagrelor, a P2Y12 inhibitor, suggesting a critical role for platelet activation [13, 
14]. Whether exposed VSMCs are reacting to releasates from activated platelets in plasma, as 
well as reacting to phagocytosed platelets apart from their miRNA cargo, remains to be 
determined. 
The authors hone in on miR-223, a miRNA highly enriched in platelets but also expressed 
in other cells, and shown previously to be internalized from the circulation by VSMCs, leading to 
growth inhibition [15]. Plasma miR-223 in healthy human donors was also shown to be 
predominantly contained in extracellular vesicle (EV)-free ribonucleoprotein complexes, and only 
partially contained in MVs or exosomes [16]. Thus, effects of miR-223 depletion, including global 
knockout or a background of induced diabetes mellitus, may reflect direct loss of blood-derived 
miR-223 in VSMCs independent from platelets as a source. As P2Y12 is a miR-223 target, miR-
223 may inhibit neointimal hyperplasia through multiple pathways including direct modulation of 
platelet activation by P2Y12 knockdown in megakaryocytes and platelets, as well as effects on 
VSMCs.  
The mechanisms of platelet uptake, miRNA transfer and utilization by the VSMCs are 
unknown. How VSMCs, beneath a thick intima in large arteries, become exposed directly to large 
plasma-borne cellular material following endothelial denudation is not clear, and to our knowledge 
phagocytic properties of VSMCs have not previously been described. Another question is how 
the encapsulated miRNAs, apparently entrapped in the endosome/lysosome system in VSMCs, 
are exposed to target cell mRNAs in the cytosol to regulate translation. Further studies with 
antibody-based labeling or live imaging of the platelet-encompassing compartments will go a long 
way towards mapping the trafficking patterns and the ultimate fates of internalized platelets or 






The relevance of RNA to short-lived anucleate platelet biology was and continues to be 
an open question. Platelet RNAs can serve as biomarkers of disease, as indicators of 
megakaryocyte gene expression, or as clues to identifying regulators of platelet function. 
Evidence of platelet protein translation under resting or stimulated conditions suggests that 
platelet RNAs could serve similar roles as they do in nucleated cells. However, (mi)RNA delivery 
from platelets to heterologous cells suggests that platelet RNA content can also have a profound 
impact on the biology of long-lived, nucleated cells undergoing continuous protein synthesis for 
cellular maintenance and in response to the environment. This, combined with the observation 
that platelets could take up circulating RNAs from the environment, make the platelet RNA profile 
both an indicator and effector of cardiovascular health. 
More work along the lines of Michael et al. and Zeng et al., needs to be performed to 
demonstrate and explain the in vivo relevance of platelet RNA transfer, particularly of long-lived 
miRNAs. In the circulation, blood and vascular cells are continuously exposed to circulating MVs, 
and in vitro experiments in cultured cells in static media may react to several stimuli when MV 
preparations are added, including bioactive lipids, surface proteins, or other non-vesicle plasma 
components. The array of vascular cells exposed to platelet RNAs, and the physiological and 
pathophysiological contexts in which exposure occurs, have not been fully mapped. Cellular 
mechanisms and molecular drivers of platelet, PMV, or extracellular vesicle-free ribonuclear 
protein complex internalization are still poorly understood. Conserved mechanisms have yet to 
emerge and conversely putative cell type-specific mechanisms may provide a further point of 
regulation. Moreover, the temporal dynamics of platelet miRNA transfer in vivo demand further 
exploration, as this speaks directly to the levels of platelet-derived miRNAs available to locate 
and modulate mRNA targets over time. Finally, the identities and quantities of transferred 
miRNAs, and those of their cognate mRNA targets in recipient cells, need to be determined in 
8 
 
each case. These issues lead straight to the central question of the physiological consequences 
of horizontal miRNA transfer: how does a cohort of transferred miRNAs affect the translational 
landscape of recipient cells to modulate function. Emergent technologies, in particular next 
generation RNA sequencing and better in vivo imaging, will continue to bring us closer to 
understanding the integrative physiology of horizontal platelet miRNA transfer in cardiovascular 
health and disease. 
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